Lentinan (LNT) treatment reduced the ratio of Bax/Bcl-2 protein and caspase-3 activity, ameliorated oxidative stress, and reduced lipid deposition in both PA-induced AML-12 cells and HFD-induced mouse livers. This evidence concerns the gene BCL2 and acute myeloid leukemia.